Curie.Bio
Molly Cole, Ph.D., currently serves as a Senior Associate at Curie.Bio since September 2024. Prior experience includes leading business development and R&D strategy at Shinobi Therapeutics from April 2023 to September 2024, and working as a Research Associate at F-Prime Capital from May 2022 to April 2023, where contributions focused on early-stage biotech investments and collaborations with Shinobi Therapeutics. Academic credentials include a Ph.D. in Immunology from Yale University, where research involved transcriptional regulation in T cell-driven inflammation, and a BA in Cell/Cellular and Molecular Biology from the University of Pennsylvania, during which CAR T-cell constructs were engineered to enhance functional persistence and efficacy.
This person is not in the org chart
This person is not in any teams
Curie.Bio
2 followers
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.